Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502565 | 1.00 | TSHR (0.58) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL4180430 | 0.90 | TSHR (0.61) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL26841751 | 0.90 | TSHR (0.56) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL272650 | 0.90 | TSHR (0.61) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL28196295 | 0.90 | TSHR (0.56) | TSHRCASP6L3MBTL1TDP1CES2 | |
| Hydrochloric Acid SCHEMBL11774750 | 0.89 | TSHR (0.59) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL14993474 | 0.87 | TSHR (0.53) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL2240139 | 0.87 | TSHR (0.53) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL29502323 | 0.87 | TSHR (0.53) | TSHRCASP6L3MBTL1TDP1CES2 | |
| SCHEMBL5115680 | 0.85 | TSHR (0.51) | TSHRCASP6L3MBTL1TDP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250154140-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | Sunnybrook Research Institute (CA) | 2025-05-15 | — | — | US | disclosed |
| EP-4479383-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | Sunnybrook Research Institute (CA) | 2024-12-25 | — | — | EP | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023155019-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | Sunnybrook Research Institute (CA) | 2023-08-24 | — | — | WO | disclosed |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-103958498-A | Aminopyrimidine derivatives as LRRK2 modulators | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | TSHR 3298/4885CASP6 953/4885L3MBTL1 4527/4885 |
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | TSHR 629/4885CASP6 2180/4885L3MBTL1 398/4885 |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | TSHR 1439/4885CASP6 2941/4885L3MBTL1 744/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | TSHR 334/4885CASP6 2179/4885L3MBTL1 3031/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | TSHR 3298/4885CASP6 953/4885L3MBTL1 4527/4885 |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | PPIA, S100A4, S100A6 | TSHR 4066/4885CASP6 2212/4885L3MBTL1 1481/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885CASP6 323/4885L3MBTL1 1394/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | TSHR 2572/4885CASP6 1303/4885L3MBTL1 154/4885 |
| US-20250154140-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | BAK1, BAX, BCL2 | TSHR 4782/4885CASP6 52/4885L3MBTL1 2944/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885CASP6 323/4885L3MBTL1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.